{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:29:00Z","timestamp":1790357340373,"version":"4.1.0"},"reference-count":15,"publisher":"Wiley","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Skin Cancer"],"published-print":{"date-parts":[[2014]]},"abstract":"<jats:p><jats:italic>Background<\/jats:italic>. Cutaneous malignant melanoma (CMM) is a heterogeneous disease, acknowledged for its lack of predictability regarding clinical evolution. In order to appreciate a patient\u2019s individual prognosis, an attempt is made to find new tumor markers that parallel the disease progression.<jats:italic>Objective<\/jats:italic>. To identify if melanoma inhibitory activity (MIA) protein could represent a tool for selecting high risk early stages melanoma patients.<jats:italic>Method<\/jats:italic>. Between 2008 and 2013, 155 patients with CMM were treated in our clinic. 84 of them were classified into stages I and II, according to TNM 2009. MIA serum concentration was measured in all patients and 50 healthy donors. A cut-off value of 9.4\u2009ng\/ml was established using the ROC curve.<jats:italic>Results<\/jats:italic>. All patients were followed up by periodic investigations every 6 months. We have noticed that 66% of patients with MIA serum values at diagnosis greater than 9.4\u2009ng\/mL have relapsed, while only 5% of patients with MIA serum concentration below the estimated threshold, recurred during the follow-up period<mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\"><mml:mo stretchy=\"false\">(<\/mml:mo><mml:mi>P<\/mml:mi><mml:mo>=<\/mml:mo><mml:mn>0.000<\/mml:mn><mml:mo stretchy=\"false\">)<\/mml:mo><\/mml:math>. The death risk was 12 times higher in pathological MIA group of patients<mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M2\"><mml:mo stretchy=\"false\">(<\/mml:mo><mml:mi>P<\/mml:mi><mml:mo>=<\/mml:mo><mml:mn>0.0001<\/mml:mn><mml:mo stretchy=\"false\">)<\/mml:mo><\/mml:math>.<jats:italic>Conclusions<\/jats:italic>. Our data suggest that MIA is an independent prognostic factor for patients with localized CMM.<\/jats:p>","DOI":"10.1155\/2014\/843214","type":"journal-article","created":{"date-parts":[[2014,6,22]],"date-time":"2014-06-22T17:03:58Z","timestamp":1403456638000},"page":"1-5","source":"Crossref","is-referenced-by-count":23,"title":["Prognostic Value of Melanoma Inhibitory Activity Protein in Localized Cutaneous Malignant Melanoma"],"prefix":"10.1155","volume":"2014","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0596-9676","authenticated-orcid":true,"given":"Angela","family":"Sandru","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, \u201cAlexandru Trestioreanu\u201d Oncologic Institute, Fundeni Street, No. 252, Sector 2, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0083-8992","authenticated-orcid":true,"given":"Eugenia","family":"Panaitescu","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics and Biostatistics, \u201cCarol Davila\u201d University of Medicine and Pharmacy, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silviu","family":"Voinea","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, \u201cAlexandru Trestioreanu\u201d Oncologic Institute, Fundeni Street, No. 252, Sector 2, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madalina","family":"Bolovan","sequence":"additional","affiliation":[{"name":"Department of Carcinogenesis and Molecular Biology, \u201cAlexandru Trestioreanu\u201d Oncologic Institute, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adina","family":"Stanciu","sequence":"additional","affiliation":[{"name":"Department of Carcinogenesis and Molecular Biology, \u201cAlexandru Trestioreanu\u201d Oncologic Institute, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabin","family":"Cinca","sequence":"additional","affiliation":[{"name":"Department of Carcinogenesis and Molecular Biology, \u201cAlexandru Trestioreanu\u201d Oncologic Institute, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru","family":"Blidaru","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, \u201cAlexandru Trestioreanu\u201d Oncologic Institute, Fundeni Street, No. 252, Sector 2, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"issue":"4","key":"1","doi-asserted-by":"crossref","first-page":"272","DOI":"10.2174\/187569208786733866","volume":"6","year":"2008","journal-title":"Current Pharmacogenomics and Personalized Medicine"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.139.9.961"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.4799"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23794"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0749.2005.00274.x"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1038\/mp.a003970.01"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1097\/01.LAB.0000097191.12477.5D"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2011.12.005"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.3892\/ol_00000070"},{"issue":"15","key":"10","first-page":"3149","volume":"57","year":"1997","journal-title":"Cancer Research"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-200112000-00009"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e32831bc78c"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024632"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2011.01219.x"},{"issue":"3","key":"15","first-page":"1779","volume":"25","year":"2005","journal-title":"Anticancer Research"}],"container-title":["Journal of Skin Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/jsc\/2014\/843214.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/jsc\/2014\/843214.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/jsc\/2014\/843214.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T11:22:19Z","timestamp":1498130539000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.hindawi.com\/journals\/jsc\/2014\/843214\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":15,"alternative-id":["843214","843214"],"URL":"https:\/\/doi.org\/10.1155\/2014\/843214","relation":{},"ISSN":["2090-2905","2090-2913"],"issn-type":[{"value":"2090-2905","type":"print"},{"value":"2090-2913","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}